Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects

doi:10.3748/wjg.v20.i16.4526

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 16

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11143)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

580

WORD

349

HTML

7777

Figures (1-6)

157

Tables (1-3)

130

Sum=8993

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1207

Download

943

Sum=2150

Apr 28, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 28, 2014; 20(16): 4526-4535
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4526

Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects

Jan Trøst Jørgensen

Jan Trøst Jørgensen, Dx-Rx Institute, 3480 Fredensborg, Denmark

Author contributions: Jørgensen JT contributed solely this paper.

Correspondence to: Jan Trøst Jørgensen, MSc Pharm, PhD, Dx-Rx Institute, Baunevaenget 76, 3480 Fredensborg, Denmark. jan.trost@dx-rx.dk

Telephone: +45-40-747846 Fax: +45-48-480528

Received: September 10, 2013
Revised: November 18, 2013
Accepted: January 2, 2014
Published online: April 28, 2014

Core Tip

Core tip: Amplification of the human epidermal growth factor receptor 2 (HER2) gene and overexpression of the HER2 protein can be detected in 15%-20% of patients with gastric and gastroesophageal junction (GEJ) cancer. Recently, HER2 has proven to be an important target for treatment with trastuzumab in these patients, and a positive HER2 status seems to possess both prognostic and predictive properties. A number of new compounds directed towards HER2 and other members of the HER family is currently under development. This review will discuss the current status of HER2 in gastric and GEJ cancer and the future direction in relation to HER2 target therapy.